AI-powered neurotechnologies raise hopes and fears for health and privacy in Geneva 

Neurotechnologies integrating artificial intelligence (AI) can treat diseases such as Parkinson's and depression and improve mental well-being, but they can also alter the brain and read the mind. From Switzerland, the global community is pushing to regulate them, especially when in the hands of private companies like Elon Musk's Neuralink. The first electrode capable of recording brain activity was implanted in a human skull in 1924. A century later, neurotechnologies powered by artificial intelligence (AI) are now able to restore speech and mobility to people suffering from aphasia and motor disabilities. Integrating AI into brain-interfacing devices enables the interpretation of complex neural data in real-time and to tailor responses to individual patient needs. This innovation holds promise for expanding treatment options for neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease. While these technological advancements offer hope, they also raise serious ...